JENNIFER FOSTER to Neuroblastoma
This is a "connection" page, showing publications JENNIFER FOSTER has written about Neuroblastoma.
Connection Strength
6.065
-
A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019. Pediatr Blood Cancer. 2024 Jan; 71(1):e30732.
Score: 0.605
-
The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. Int J Mol Sci. 2021 Jun 18; 22(12).
Score: 0.515
-
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 07 01; 27(13):3543-3548.
Score: 0.502
-
Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant. J Pediatr Hematol Oncol. 2020 10; 42(7):e569-e574.
Score: 0.490
-
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
Score: 0.484
-
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett. 2019 08 10; 457:129-141.
Score: 0.445
-
The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Opin Drug Saf. 2018 Dec; 17(12):1257-1262.
Score: 0.431
-
Dinutuximab for the treatment of pediatric patients with neuroblastoma. Drugs Today (Barc). 2017 Sep; 53(9):469-476.
Score: 0.396
-
Neuroblastoma. BMJ. 2017 05 03; 357:j1863.
Score: 0.387
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
Score: 0.166
-
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol. 2023 01 20; 41(3):508-516.
Score: 0.141
-
Renal function in abdominal neuroblastoma patients undergoing proton radiotherapy. Pediatr Blood Cancer. 2023 01; 70(1):e29981.
Score: 0.140
-
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nat Commun. 2022 06 28; 13(1):3728.
Score: 0.138
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.138
-
Associations of demographic and perinatal factors with childhood neuroblastoma in Texas, 1995-2011. Cancer Epidemiol. 2022 06; 78:102165.
Score: 0.136
-
Thoracoscopic Resection of Thoracic Inlet Neuroblastic Tumors in Young Children. J Laparoendosc Adv Surg Tech A. 2021 Dec; 31(12):1475-1479.
Score: 0.132
-
Characteristics of benign neuroblastic tumors: Is surgery always necessary? J Pediatr Surg. 2022 Aug; 57(8):1538-1543.
Score: 0.129
-
Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev. 2021 03; 41(2):961-1021.
Score: 0.123
-
Severe COVID-19 infection in a child receiving immunotherapy for cancer. Pediatr Blood Cancer. 2021 03; 68(3):e28710.
Score: 0.122
-
Blood product administration during high risk neuroblastoma therapy. Pediatr Hematol Oncol. 2020 Feb; 37(1):5-14.
Score: 0.116
-
A case series of pediatric oncology patients undergoing successful rapid etoposide desensitization. Pediatr Allergy Immunol. 2019 08; 30(5):579-582.
Score: 0.113
-
Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma. Pediatr Blood Cancer. 2019 08; 66(8):e27786.
Score: 0.111
-
Evolving biopsy techniques for the diagnosis of neuroblastoma in children. J Pediatr Surg. 2018 Nov; 53(11):2235-2239.
Score: 0.103